The client had a phase II vasopeptidase inhibitor (angiotensin-converting enzyme/neutral endopeptidase) in the pipeline, but did not have very strong in-house cardiovascular expertise. This made it mission-critical for the client to gain an objective background overview of this clinical landscape.
Eight competitors had been identified already any or all of them could possibly launch a new competitive entrant in this drug class. While a significant amount of information was being presented and published for omapatrilat (Vanlev), one of the competitor drugs, angioedema problems had been demonstrated in the side effect profile of this particular drug. Solutions:
Our Clinical Intelligence team reviewed relevant medical meeting data and benchmarked it against published literature, and this extensive analysis identified a total of 32 potential competitors conducting clinical trials - not just eight.
Further research revealed that data relating to these competitors already had been presented at 15 different worldwide medical meetings, and published in 12 different journals.
The Clinical Intelligence team conducted an additional in-depth analysis of all data and determined that the changes in the amount of inhibition on angiotensin-converting enzyme or neutral endopeptidase failed to improve the side effect profile.
In conclusion, the client received a complete, critical look at the clinical landscape, allowing client to determine their course of action. Client Payoff:
After reviewing the Retrospective Data Analysis of the clinical landscape and incorporating the findings with their internal data, the client called a stop to further trials for their phase II vasopeptidase inhibitor.
This decision saved the client millions of dollars in trial work and related costs for a drug that would not be likely to receive approval from the Food and Drug Administration.
Client Scenario and Objectives:
Solutions:
Client Payoff:
)